Revenue Recognition and Collaborative Arrangements (Tables)

9 Months Ended

Sep. 30, 2020

Revenue Recognition and Collaborative Arrangements

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2020		2019		2020		2019
Royalties from a related party — RELVAR/BREO	$	63,893	$	46,433	$	165,612	$	136,259
Royalties from a related party — ANORO		11,882		11,548		32,931		30,753
Royalties from a related party — TRELEGY		16,375		11,230		48,143		28,401
Total royalties from a related party		92,150		69,211		246,686		195,413
Less: amortization of capitalized fees paid to a related party		(3,456)		(3,456)		(10,368)		(10,368)
Royalty revenue		88,694		65,755		236,318		185,045
Strategic alliance  — MABA program		—		—		10,000		—
Total net revenue from GSK	$	88,694	$	65,755	$	246,318	$	185,045